1. Home
  2. MLYS vs DV Comparison

MLYS vs DV Comparison

Compare MLYS & DV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • DV
  • Stock Information
  • Founded
  • MLYS 2019
  • DV 2008
  • Country
  • MLYS United States
  • DV United States
  • Employees
  • MLYS N/A
  • DV N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • DV Computer Software: Prepackaged Software
  • Sector
  • MLYS Health Care
  • DV Technology
  • Exchange
  • MLYS Nasdaq
  • DV Nasdaq
  • Market Cap
  • MLYS 3.1B
  • DV 2.5B
  • IPO Year
  • MLYS 2023
  • DV 2021
  • Fundamental
  • Price
  • MLYS $40.00
  • DV $12.11
  • Analyst Decision
  • MLYS Strong Buy
  • DV Buy
  • Analyst Count
  • MLYS 6
  • DV 18
  • Target Price
  • MLYS $42.60
  • DV $18.83
  • AVG Volume (30 Days)
  • MLYS 1.3M
  • DV 3.3M
  • Earning Date
  • MLYS 11-10-2025
  • DV 11-07-2025
  • Dividend Yield
  • MLYS N/A
  • DV N/A
  • EPS Growth
  • MLYS N/A
  • DV N/A
  • EPS
  • MLYS N/A
  • DV 0.31
  • Revenue
  • MLYS N/A
  • DV $714,259,000.00
  • Revenue This Year
  • MLYS N/A
  • DV $18.55
  • Revenue Next Year
  • MLYS N/A
  • DV $11.88
  • P/E Ratio
  • MLYS N/A
  • DV $38.58
  • Revenue Growth
  • MLYS N/A
  • DV 16.54
  • 52 Week Low
  • MLYS $8.24
  • DV $10.73
  • 52 Week High
  • MLYS $44.80
  • DV $23.11
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 53.93
  • DV 53.04
  • Support Level
  • MLYS $41.74
  • DV $10.73
  • Resistance Level
  • MLYS $44.60
  • DV $11.37
  • Average True Range (ATR)
  • MLYS 2.22
  • DV 0.33
  • MACD
  • MLYS -0.83
  • DV 0.24
  • Stochastic Oscillator
  • MLYS 46.44
  • DV 89.49

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About DV DoubleVerify Holdings Inc.

DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.

Share on Social Networks: